Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease

Mattsson, Niklas LU orcid ; Eriksson, Oscar ; Lindberg, Olof LU ; Schöll, Michael LU ; Lampinen, Björn LU ; Nilsson, Markus LU ; Insel, Philip S. LU ; Lautner, Ronald ; Strandberg, Olof LU and van Westen, Danielle LU orcid , et al. (2018) In Neurobiology of Aging 71. p.81-90
Abstract

Apolipoprotein (APOE) ε4 is a major genetic risk factor for Alzheimer's disease (AD), but its importance for the clinical and biological heterogeneity in AD is unclear, particularly at the prodromal stage. We analyzed 151 prodromal AD patients (44 APOE ε4-negative and 107 APOE ε4-positive) from the BioFINDER study. We tested cognition, 18F-flutemetamol β-amyloid (Aβ) positron emission tomography, cerebrospinal fluid biomarkers of Aβ tau and neurodegeneration, and magnetic resonance imaging of white matter pathology and brain structure. Despite having similar cortical Aβ-load and baseline global cognition (mini mental state examination), APOE ε4-negative prodromal AD had more nonamnestic cognitive impairment, higher cerebrospinal fluid... (More)

Apolipoprotein (APOE) ε4 is a major genetic risk factor for Alzheimer's disease (AD), but its importance for the clinical and biological heterogeneity in AD is unclear, particularly at the prodromal stage. We analyzed 151 prodromal AD patients (44 APOE ε4-negative and 107 APOE ε4-positive) from the BioFINDER study. We tested cognition, 18F-flutemetamol β-amyloid (Aβ) positron emission tomography, cerebrospinal fluid biomarkers of Aβ tau and neurodegeneration, and magnetic resonance imaging of white matter pathology and brain structure. Despite having similar cortical Aβ-load and baseline global cognition (mini mental state examination), APOE ε4-negative prodromal AD had more nonamnestic cognitive impairment, higher cerebrospinal fluid levels of Aβ-peptides and neuronal injury biomarkers, more white matter pathology, more cortical atrophy, and faster decline of mini mental state examination, compared to APOE ε4-positive prodromal AD. The absence of APOE ε4 is associated with an atypical phenotype of prodromal AD. This suggests that APOE ε4 may impact both the diagnostics of AD in early stages and potentially also effects of disease-modifying treatments.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, APOE, Biomarkers, Cognition, Imaging, Prodromal
in
Neurobiology of Aging
volume
71
pages
10 pages
publisher
Elsevier
external identifiers
  • pmid:30107289
  • scopus:85051369591
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2018.07.003
language
English
LU publication?
yes
id
906d42cf-682a-49a2-bfdf-c9f4b285f870
date added to LUP
2018-09-06 10:44:57
date last changed
2024-04-01 09:58:19
@article{906d42cf-682a-49a2-bfdf-c9f4b285f870,
  abstract     = {{<p>Apolipoprotein (APOE) ε4 is a major genetic risk factor for Alzheimer's disease (AD), but its importance for the clinical and biological heterogeneity in AD is unclear, particularly at the prodromal stage. We analyzed 151 prodromal AD patients (44 APOE ε4-negative and 107 APOE ε4-positive) from the BioFINDER study. We tested cognition, 18F-flutemetamol β-amyloid (Aβ) positron emission tomography, cerebrospinal fluid biomarkers of Aβ tau and neurodegeneration, and magnetic resonance imaging of white matter pathology and brain structure. Despite having similar cortical Aβ-load and baseline global cognition (mini mental state examination), APOE ε4-negative prodromal AD had more nonamnestic cognitive impairment, higher cerebrospinal fluid levels of Aβ-peptides and neuronal injury biomarkers, more white matter pathology, more cortical atrophy, and faster decline of mini mental state examination, compared to APOE ε4-positive prodromal AD. The absence of APOE ε4 is associated with an atypical phenotype of prodromal AD. This suggests that APOE ε4 may impact both the diagnostics of AD in early stages and potentially also effects of disease-modifying treatments.</p>}},
  author       = {{Mattsson, Niklas and Eriksson, Oscar and Lindberg, Olof and Schöll, Michael and Lampinen, Björn and Nilsson, Markus and Insel, Philip S. and Lautner, Ronald and Strandberg, Olof and van Westen, Danielle and Zetterberg, Henrik and Blennow, Kaj and Palmqvist, Sebastian and Stomrud, Erik and Hansson, Oskar}},
  issn         = {{0197-4580}},
  keywords     = {{Alzheimer's disease; APOE; Biomarkers; Cognition; Imaging; Prodromal}},
  language     = {{eng}},
  month        = {{11}},
  pages        = {{81--90}},
  publisher    = {{Elsevier}},
  series       = {{Neurobiology of Aging}},
  title        = {{Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1016/j.neurobiolaging.2018.07.003}},
  doi          = {{10.1016/j.neurobiolaging.2018.07.003}},
  volume       = {{71}},
  year         = {{2018}},
}